Cargando…
Five years of the CiPA project (2013–2018): what did we learn?
Cases of drug-induced QT prolongation and sudden cardiac deaths resulted in market withdrawal of many drugs and world-wide regulatory changes through accepting the ICH guidelines E14 and S7B. However, because the guidelines were not comprehensive enough to cover the electrophysiological changes by d...
Autor principal: | Yim, Dong-Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Clinical Pharmacology and Therapeutics
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989253/ https://www.ncbi.nlm.nih.gov/pubmed/32055567 http://dx.doi.org/10.12793/tcp.2018.26.4.145 |
Ejemplares similares
-
CiPA-compliant assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine
por: Amuzescu, Bogdan, et al.
Publicado: (2021) -
Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept
por: Thomet, Urs, et al.
Publicado: (2021) -
Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative
por: Park, Jin-Sol, et al.
Publicado: (2019) -
Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs
por: Han, Sungpil, et al.
Publicado: (2019) -
Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
por: Li, Zhihua, et al.
Publicado: (2018)